Alnylam Pharmaceuticals (United States)
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Alnylam Pharmaceuticals (United States), United States, covering academic research published from 2003 to 2024. Read More.
Open Access Percentage
61%
Total
Publications
894
Total Open
Publications
541
Total
Citations
78K
Open Access
Percentage
61%
Total
Publications
894
Total Open
Publications
541
Total
Citations
78K
Breakdown
Publisher Open
17%
Both
32%
Other Platform Open
12%
Closed
39%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 31%
136
Hybrid 36%
157
No Guarantees 33%
142
Other Platform Open
Domain 83%
323
Institution 22%
85
Preprint 14%
55
Other Internet 9%
36
Public 6%
25
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 323 |
Europe PMC | Domain | 173 |
bioRxiv | Preprint | 28 |
University College London - UCL Discovery | Institution | 26 |
DOI | Other Internet | 20 |
Semantic Scholar | Public | 19 |
Massachusetts Institute of Technology - DSpace@MIT | Institution | 16 |
medRxiv | Preprint | 14 |
Research Square | Preprint | 12 |
St George's University of London - St George's Online Research Archive | Institution | 10 |